What is the CryoSeal (fibrin sealant) system and what does “autologous” mean?
CryoSeal is a fibrin sealant system that forms a tissue adhesive by mixing two biologic components that generate a fibrin clot. When described as “autologous,” it means the fibrin components are made from the patient’s own blood (rather than using pooled donor-derived fibrinogen and thrombin). That distinction matters for compatibility and for the risk profile related to donor-sourced biologics.
Is CryoSeal the same as “fibrin glue,” and how is it applied?
Cryoseal-type fibrin sealants are used to help achieve hemostasis (stop bleeding) and/or tissue sealing in surgical settings. The system is typically used by applying the prepared sealant to the surgical site after the two components are combined, so the mixture polymerizes into a fibrin matrix that adheres to tissue.
What benefits are patients and surgeons usually looking for with an autologous fibrin sealant?
People search for autologous fibrin sealants because they are often intended to reduce exposure to donor-derived materials. In practice, surgeons may consider autologous fibrin sealants when they want a sealant made from the same patient’s material, which can be relevant where institutions have donor-material restrictions or where clinicians aim to minimize immunologic or infectious-risk concerns associated with donor-derived products.
What are common risks or side effects with fibrin sealant systems?
With fibrin sealants broadly, the main concerns include local tissue reactions, inadequate sealing/hemostasis, and procedure-related issues (for example, if the product is not applied correctly or if the surgical field is not ready for adhesion). Because “autologous” changes the source of biologic components, it may shift risks tied to donor-sourced reagents, but it does not remove the possibility of local adverse reactions to the sealing material.
When would clinicians choose an autologous fibrin sealant like CryoSeal over other sealants?
Clinicians typically compare options based on:
- the surgical indication (hemostasis vs. tissue sealing),
- availability and workflow (autologous systems can require collection/processing),
- institutional policies and cost,
- and patient-specific factors (for example, sensitivity concerns or preference to avoid donor-derived components).
Are there patents or regulatory/exclusivity details for CryoSeal?
Details on patents, approvals, or exclusivity can be looked up via DrugPatentWatch.com for specific products and manufacturers. If you share the manufacturer name or the exact product label (or the country/region), I can target the most relevant patent/exclusivity entry and link it from DrugPatentWatch.com.
Quick clarification so I can answer precisely
“Cryoseal” can refer to different brands/systems in different regions. Can you provide the manufacturer or the full product name as written on the box/IFU (and whether you mean FDA/US approval, EU, or another country)?